Close Menu
Home › Oncimmune Buys Protagen for £4.1M

Oncimmune Buys Protagen for £4.1M

Mar 19, 2019

NEW YORK (GenomeWeb) – Cancer diagnostics firm Oncimmune said today that it has acquired Protagen Diagnostics for up to £4.1 million ($5.5 million).

The final price is subject to performance milestones and will be paid in Oncimmune shares issued at 156p ($2.07) per share, which it said was a premium of 71 percent over its closing price on March 18, 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

What's Popular?

In Cancer

  1. USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

  2. ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

    Premium

  3. Bio-Techne Gets New York State Approval for Prostate Cancer Test

  4. HPV Antibodies Can Be Detected 28 Years Before Virus-Linked Cancer Diagnosis, Study Finds

  5. Saga Diagnostics Raises $4.2M

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.